Judge Karen Martson has been appointed to oversee a massive, multi-district lawsuit, against Novo Nordisk and Eli Lilly, Both drugmakers of GLP-1 class medications. Their popular diabetes and obesity medications include Ozempic, Wegovy, Mounjaro, Trulicity and Zepbound.
A Kaiser Family Foundation poll states that about one in eight U.S. adults have taken a drug belonging to the GLP-1 class of medications. The lawsuit alleges that the drugmakers neglected to adequately warn about “prolonged, life-threatening digestive dysfunction” potentially caused by their medications. Side effects include gastroparesis, severe vomiting, and gallbladder issues.
This blog is intended to provide information to the general public and to practitioners about developments that may impact Oregon class actions.
